Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab plus chemotherapy with or without synchronous low-dose radiotherapy for first-line extensive-stage small cell lung cancer
ChiCTR2400090673Phase 3Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Oct 2024
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of adebrelimab in small cell lung cancer (SCLC) (2 arms), sponsored by West China Hospital of Sichuan University. Primary endpoint: Progression-free survival by blinded independent central review. Planned start Oct 2024; status: not yet recruiting.
02
Drugs
adebrelimab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on ChiCTR2400090673.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400090673.